Suppr超能文献

采用喷雾干燥或冷冻干燥法制备时,药物-固体分散体(Soluplus®)与药物-聚乙二醇6000分散体的体外性能差异研究。

Investigation of the in vitro performance difference of drug-Soluplus® and drug-PEG 6000 dispersions when prepared using spray drying or lyophilization.

作者信息

Altamimi Mohammad A, Neau Steven H

机构信息

Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, 600 S. 43rd Street, Philadelphia, PA 19104, United States; Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.

Department of Pharmaceutical Sciences, Philadelphia College of Pharmacy, University of the Sciences, 600 S. 43rd Street, Philadelphia, PA 19104, United States.

出版信息

Saudi Pharm J. 2017 Mar;25(3):419-439. doi: 10.1016/j.jsps.2016.09.013. Epub 2016 Sep 30.

Abstract

PURPOSE

To evaluate the physicochemical and in vitro characteristics of solid dispersions using BCS II model drugs with Soluplus® and one of its component homopolymers, PEG 6000.

METHODS

Nifedipine (NIF) and sulfamethoxazole (SMX) of 99.3% and 99.5% purity, respectively, were selected as BCS II model drugs, such that an improved dissolution rate and concentration in the gastrointestinal tract should increase oral bioavailability. Soluplus® is an amorphous, tri-block, graft co-polymer with polyvinyl caprolactam, polyvinyl acetate, and polyethylene glycol (PCL:PVAc:PEG6000) in the ratio 57:30:13. PEG 6000 (BASF) is a waxy material with melting point of about 60 °C. Solid dispersions were prepared using lyophilization or spray drying techniques. Dissolution study, crystallinity content, and analysis for new chemical bond formation have been used to evaluate the dispersed materials.

RESULTS

Although each polymer improved the drug dissolution rate, dissolution from Soluplus® was slower. Enhanced dissolution rates were observed with NIF solid dispersions, but the dissolution profiles were quite different due to the selected technique, polymer, and dissolution medium. For SMX, there was similarity across the dissolution profiles despite the medium, polymer, or applied technique. Each polymer was able to maintain an elevated drug concentration over the three hour duration of the dissolution profile, i.e., supersaturation was supported by the polymer. DSC thermograms revealed no melting endotherm, suggesting that the drug is amorphous or molecularly dispersed.

CONCLUSION

NIF and SMX solid dispersions were successfully prepared by spray drying and lyophilization using Soluplus® or PEG 6000. Each polymer enhanced the drug dissolution rate; NIF dissolution rate was improved to a greater extent. Dispersions with PEG 6000 had a faster dissolution rate due to its hydrophilic nature. DSC analysis showed that no crystalline material exists in the dispersions.

摘要

目的

使用BCS II类模型药物与固体分散体Soluplus®及其一种组分均聚物聚乙二醇6000(PEG 6000),评估固体分散体的物理化学性质和体外特性。

方法

分别选用纯度为99.3%和99.5%的硝苯地平(NIF)和磺胺甲恶唑(SMX)作为BCS II类模型药物,以期提高溶出速率并增加胃肠道中的药物浓度,从而提高口服生物利用度。Soluplus®是一种无定形三嵌段接枝共聚物,由聚乙烯己内酰胺、聚醋酸乙烯酯和聚乙二醇(PCL:PVAc:PEG6000)按57:30:13的比例组成。PEG 6000(巴斯夫公司)是一种蜡质材料,熔点约为60°C。采用冻干法或喷雾干燥技术制备固体分散体。通过溶出度研究、结晶度含量测定以及新化学键形成分析来评估分散材料。

结果

尽管每种聚合物都提高了药物溶出速率,但Soluplus®的溶出速率较慢。NIF固体分散体的溶出速率有所提高,但由于所选技术、聚合物和溶出介质的不同,溶出曲线差异较大。对于SMX,尽管溶出介质、聚合物或应用技术不同,但其溶出曲线具有相似性。在溶出曲线的三小时持续时间内,每种聚合物都能够维持较高的药物浓度,即聚合物支持药物形成过饱和状态。差示扫描量热法(DSC)热谱图显示没有熔融吸热峰,表明药物为无定形或分子分散状态。

结论

采用Soluplus®或PEG 6000,通过喷雾干燥和冻干法成功制备了NIF和SMX固体分散体。每种聚合物都提高了药物溶出速率;NIF的溶出速率提高幅度更大。由于PEG 6000具有亲水性,含PEG 6000的分散体溶出速率更快。DSC分析表明分散体中不存在结晶物质。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de57/5357108/a25b96b0b912/gr1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验